The Food and Drug Administration has authorized the use of Labcorp's blood-based in-vitro diagnostic test that's works by detesting the amyloid plaques associated with the disease in certain patients.

BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its ...

To improve patient access to testing, Labcorp announced: availability of new NGS panels for myeloid, lymphoid and pan-heme indications; the launch of a Rapid AML Panel, enhancing test menu for ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its ...

Labcorp's Menopause Test and Menopause Support Program provide women with insights to guide their healthcare decisions BURLINGTON, N.C., July 24, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global ...

Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the brain-wasting ...